Nephrocare Health Services Limited (NSE: NEPHROPLUS), ISIN INE428V01029 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
NEPHROPLUS last traded at ₹703.90 (+2.18%), with a 52-week range of ₹445.00 to ₹767.95 (as of 30 Jul 2026).
Shareholding as of Jun 2026: promoters 63.85%, FIIs 8.78%, DIIs 9.05%, mutual funds 3.20%.
EquiSense Score (ECS): 91/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.